Available online on 15.12.2024 at ijmspr.com

International Journal of Medical Sciences and Pharma Research

Open Access to Medical Science and Pharma Research

Open Access **Review Article**

Screening for Thalassemia Traits in Pregnancy: The Role of Mentzer Index

Emmanuel Ifeanyi Obeagu [1]* and Getrude Uzoma Obeagu [2]

[1] Department of Medical Laboratory Science, Kampala International University, Uganda.
[2] School of Nursing Science, Kampala International University, Uganda.

Article Info:

Article History:

Received 04 Sep 2024
Reviewed 14 October 2024
Accepted 08 November 2024
Published 15 December 2024

Cite this article as:

Obeagu EI, Obeagu GU, Screening for Thalassemia Traits in Pregnancy: The Role of Mentzer Index, International Journal of Medical Sciences & Pharma Research, 2024; 10(4):50-55 *DOI: http://dx.doi.org/10.22270/ijmspr.v10i4.123*

*Address for Correspondence:

Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe

Abstract

Thalassemia traits present significant challenges during pregnancy, often leading to complications such as anemia and adverse maternal and fetal outcomes. Early identification of carriers is essential for managing these risks and providing appropriate care. This review article examines the Mentzer Index, a straightforward and cost-effective tool derived from complete blood count (CBC) parameters, which can effectively screen for thalassemia traits in pregnant women. By calculating the ratio of mean corpuscular volume (MCV) to red blood cell (RBC) count, the Mentzer Index serves as a valuable first-line screening measure, facilitating timely referrals for further diagnostic testing. The relevance of early detection is underscored by the need for informed reproductive choices and tailored management strategies. Recognizing thalassemia traits allows healthcare providers to monitor affected women closely and implement appropriate interventions, ultimately improving maternal health outcomes. Furthermore, the Mentzer Index is easily applicable in various clinical settings, particularly in resource-limited environments where access to advanced laboratory testing may be limited.

Keywords: Thalassemia, pregnancy, Mentzer Index, anemia, screening, complete blood count, maternal health, carrier detection.

Introduction

Thalassemia is a hereditary blood disorder characterized by the abnormal production of hemoglobin, leading to reduced oxygen-carrying capacity and chronic anemia. This condition is prevalent in various parts of the world, particularly in regions with high malaria prevalence, such as the Mediterranean, Middle East, and Southeast Asia. Thalassemia traits, while often asymptomatic, can pose significant health risks, especially during pregnancy, where the physiological demands on maternal health increase significantly. The need for effective screening methods for thalassemia traits in pregnant women has become paramount to prevent complications associated with this condition.[1] Pregnant women carrying thalassemia traits may experience exacerbated anemia, leading to symptoms such as fatigue, weakness, and increased susceptibility to infections. Moreover, the presence of thalassemia traits can complicate the diagnosis and management of anemia during pregnancy, particularly when distinguishing between iron deficiency anemia (IDA) and thalassemia. Both conditions share overlapping clinical features, which can lead to misdiagnosis and inappropriate treatment. Therefore, implementing effective screening strategies is essential for identifying at-risk individuals and ensuring timely interventions.[2] The Mentzer Index is a valuable tool that offers a simple and cost-effective method for screening thalassemia traits during pregnancy. Derived from complete blood count (CBC) parameters, the Mentzer Index is calculated using the ratio of mean corpuscular volume (MCV) to red blood cell (RBC) count. A low Mentzer Index value (typically <13) suggests thalassemia traits, while a higher value indicates IDA. The ease of calculation and accessibility of CBC testing make the Mentzer Index an attractive option for initial screening in clinical practice.[3] Historically, the detection of thalassemia traits relied heavily on more complex laboratory methods, such as hemoglobin electrophoresis and genetic testing. While these methods remain essential for definitive diagnosis, they can be resource-intensive and may not be readily available in all healthcare settings. The Mentzer Index provides a practical solution, allowing healthcare providers to quickly assess the likelihood of thalassemia traits during routine prenatal care. This rapid assessment can help guide subsequent diagnostic testing and management strategies.[4] Incorporating the Mentzer Index into routine prenatal screening protocols can significantly enhance the early detection of thalassemia traits. Identifying carriers early in pregnancy facilitates informed reproductive choices, allowing couples to understand the risks of passing on the condition to their offspring. Genetic counseling can empower families with knowledge about thalassemia

and inform decisions regarding prenatal diagnostic testing and management. This proactive approach can lead to improved maternal health outcomes and reduced risks of complications during pregnancy.[5]

Understanding the Mentzer Index

The Mentzer Index is a hematological tool used to differentiate between thalassemia traits and iron deficiency anemia (IDA) based on red blood cell (RBC) indices. It is calculated using a straightforward formula: **Mentzer Index = Mean Corpuscular Volume (MCV) / Red Blood Cell Count (RBC)**. This ratio is derived from complete blood count (CBC) data, which is widely available in clinical laboratories. The simplicity of this calculation makes it an attractive screening tool, particularly in settings with limited access to advanced diagnostic techniques.[6] The MCV represents the average volume of individual red blood cells, while the RBC count reflects the total number of red blood cells in a given volume of blood. The Mentzer Index typically produces values that help clinicians categorize patients into two main groups: those likely suffering from thalassemia traits and those with iron deficiency anemia. Generally, a Mentzer Index value of less than 13 suggests the presence of thalassemia traits, while values greater than 13 indicate IDA. This cutoff is based on the physiological differences between the two conditions, where thalassemia often leads to microcytic anemia with preserved or elevated RBC counts, unlike IDA, which typically presents with low MCV and low RBC counts.[7] One of the key advantages of the Mentzer Index is its ease of application in clinical practice. The calculation can be performed quickly during routine CBC evaluations, allowing for prompt identification of patients who may require further testing for thalassemia. Moreover, the Mentzer Index does not require additional blood samples or specialized equipment, making it particularly useful in resource-limited settings where access to advanced diagnostic tools may be restricted. The Mentzer Index's utility extends beyond mere screening; it also serves as a decision-making aid for healthcare providers. By identifying patients at higher risk for thalassemia traits, clinicians can initiate more comprehensive diagnostic workups, including hemoglobin electrophoresis and genetic testing. These follow-up tests provide definitive diagnoses and help inform management strategies tailored to the specific needs of the patient.[8] However, while the Mentzer Index is a valuable screening tool, it is important to consider its limitations. Various factors, such as ethnic background, hydration status, and underlying medical conditions, can influence MCV and RBC counts, potentially affecting the accuracy of the Mentzer Index. Consequently, healthcare providers should interpret the results in the context of the patient's overall clinical picture, considering other laboratory findings and individual risk factors.

Relevance of Early Thalassemia Detection in Pregnancy

Early detection of thalassemia traits during pregnancy is crucial for several reasons, primarily revolving around the health of both the mother and the developing fetus. Thalassemia can significantly affect maternal health, often leading to complications such as anemia, which can result in fatigue, reduced physical performance, and increased susceptibility to infections. These health challenges can complicate the course of pregnancy and lead to adverse outcomes if not properly managed.[9] One of the primary concerns with undiagnosed thalassemia in pregnancy is the potential for severe anemia. Pregnant women experience physiological changes, including increased blood volume, which can mask underlying hematological disorders. As a result, thalassemia traits may go unrecognized, leading to the underestimation of anemia severity. This oversight can delay appropriate management strategies, increasing the risk of complications like preterm labor, low birth weight, and postpartum hemorrhage. Timely screening allows for proper monitoring and management, ultimately reducing these risks and promoting better maternal health. Furthermore, early detection of thalassemia traits empowers healthcare providers to offer tailored care and counseling. When women are identified as carriers of thalassemia, healthcare teams can provide education on the implications of the condition, including the risks of passing the trait to their offspring. This information is vital for informed decision-making regarding prenatal testing options, such as chorionic villus sampling (CVS) or amniocentesis, which can determine whether the fetus is affected by thalassemia major. Understanding these options allows parents to prepare for potential outcomes and make choices aligned with their values and circumstances.[10] The importance of early detection extends to public health implications as well. Thalassemia is a genetic disorder, and identifying carriers within the population helps inform screening programs and genetic counseling initiatives. By raising awareness of thalassemia and its implications during prenatal care, healthcare providers can engage in community outreach to educate potential parents about the condition. Such initiatives are particularly relevant in regions with high thalassemia prevalence, contributing to healthier pregnancies and families.[11] Additionally, early detection of thalassemia traits facilitates appropriate management of anemia during pregnancy. Treatment options, such as iron supplementation or folic acid, can be tailored to the individual needs of the patient based on accurate diagnosis. Differentiating between thalassemia traits and iron deficiency anemia is crucial, as inappropriate iron supplementation in thalassemia can lead to iron overload, resulting in further complications. Thus, timely identification helps avoid unnecessary treatments and complications associated with mismanagement.

Mentzer Index Application in Clinical Settings

The application of the Mentzer Index in clinical settings has garnered attention as a practical and efficient screening tool for identifying thalassemia traits, particularly in pregnant women. Given the complexities associated with anemia diagnosis and management during pregnancy, the Mentzer Index serves as a valuable first step in differentiating between

thalassemia and iron deficiency anemia (IDA). Its straightforward calculation—using mean corpuscular volume (MCV) and red blood cell (RBC) count—enables healthcare providers to quickly assess patients and determine the need for further diagnostic testing.[12]

Integration into Routine Screening Protocols

In many healthcare systems, routine blood tests, such as complete blood counts, are performed during early pregnancy visits. The Mentzer Index can be easily integrated into these existing protocols. By calculating the index during these routine CBC evaluations, clinicians can efficiently identify women at higher risk for thalassemia traits. A low Mentzer Index value (<13) can prompt further investigation, such as hemoglobin electrophoresis or genetic testing, while a higher value (>13) may suggest IDA, leading to different management approaches.[13]

Guiding Clinical Decision-Making

The Mentzer Index not only aids in screening but also plays a critical role in guiding clinical decision-making. For example, when a patient presents with anemia during pregnancy, the calculated Mentzer Index can provide immediate insight into the likely etiology of the anemia. If thalassemia traits are suspected based on a low Mentzer Index, healthcare providers can initiate appropriate management strategies, including close monitoring and counseling regarding the implications of the condition. This proactive approach can enhance patient care by allowing for timely interventions that can mitigate complications associated with thalassemia during pregnancy.[14]

Educating Healthcare Providers

The successful application of the Mentzer Index in clinical settings hinges on the education and training of healthcare providers. Clinicians must be knowledgeable about interpreting the Mentzer Index and recognizing its limitations. Variability in hematological parameters among different populations can influence the accuracy of the index, necessitating careful consideration of patient-specific factors. Providing training sessions and resources for healthcare professionals can enhance their understanding of thalassemia screening and improve overall maternal care.[15]

Resource-Limited Settings

The Mentzer Index is particularly valuable in resource-limited settings, where access to advanced diagnostic technologies may be constrained. In such environments, the ease of calculating the Mentzer Index from routine CBC data allows for effective screening without the need for extensive laboratory facilities. This capability can be especially beneficial in rural or underserved areas, where early identification of thalassemia traits can lead to better management of anemia and improved maternal health outcomes.[16]

Patient Engagement and Education

In addition to its clinical utility, the Mentzer Index can facilitate patient engagement and education. When women are informed about the importance of thalassemia screening and how the Mentzer Index aids in identifying potential risks, they are more likely to participate actively in their healthcare. Educating patients about the implications of being a thalassemia carrier can empower them to make informed decisions regarding their reproductive choices and prenatal care.[17]

Comparison of the Mentzer Index with Other Diagnostic Indices

The Mentzer Index is widely used as a screening tool for differentiating between thalassemia traits and iron deficiency anemia (IDA) based on red blood cell indices. While it offers several advantages, it is important to compare its efficacy with other diagnostic indices that are also utilized in the evaluation of microcytic anemia. This comparison can provide insights into the strengths and limitations of the Mentzer Index and highlight its role in clinical practice.

1. Mentzer Index vs. RDW (Red Cell Distribution Width)

The Red Cell Distribution Width (RDW) is another important parameter derived from a complete blood count (CBC) that reflects the variation in size among red blood cells. In the context of anemia, RDW values can help differentiate between thalassemia and IDA. Typically, IDA is associated with an elevated RDW, as the body produces a mix of small, microcytic red blood cells and normal-sized cells due to fluctuating iron availability. In contrast, patients with thalassemia traits usually have a normal or slightly elevated RDW.[17] While both the Mentzer Index and RDW can aid in distinguishing between the two conditions, the RDW has the advantage of being less influenced by individual hematological variations. However, the RDW may require further interpretation and may not provide the clear cutoff values that the Mentzer Index offers, making the latter a more straightforward initial screening tool.

2. Mentzer Index vs. the Shine and Lal Index

The Shine and Lal Index is another diagnostic tool used to differentiate thalassemia from IDA. It is calculated using the formula: **Shine and Lal Index = (MCV - 30) / RBC**. Like the Mentzer Index, the Shine and Lal Index aims to determine the likelihood of thalassemia based on red blood cell parameters. A Shine and Lal Index value of less than 1 indicates thalassemia, while a value greater than 1 suggests IDA. While both indices serve a similar purpose, the Mentzer Index is often preferred due to its simplicity and ease of calculation. Furthermore, the thresholds for differentiation are more clearly defined in the Mentzer Index, which may enhance its utility in clinical practice. However, some studies suggest that the Shine and Lal Index may have higher sensitivity for detecting thalassemia, indicating that using multiple indices in conjunction may provide a more comprehensive assessment.[18]

3. Mentzer Index vs. the Ferritin Level

Ferritin is a blood protein that reflects the amount of stored iron in the body and is commonly measured to assess iron status. Low ferritin levels are indicative of

iron deficiency, while normal or high levels suggest that anemia is likely due to other causes, such as thalassemia. While ferritin testing is essential for diagnosing IDA, it does not provide information about red blood cell morphology, which is critical for distinguishing between IDA and thalassemia. The Mentzer Index, on the other hand, directly assesses red blood cell characteristics, making it a complementary tool to ferritin measurements. Together, they can provide a more comprehensive view of a patient's hematological status, facilitating accurate diagnosis and management.[19]

4. Mentzer Index vs. Hemoglobin Electrophoresis

Hemoglobin electrophoresis is a definitive diagnostic test used to identify different types of hemoglobin and confirm the presence of thalassemia. While the Mentzer Index is useful as an initial screening tool, hemoglobin electrophoresis provides conclusive results regarding hemoglobin variants. Although the Mentzer Index can guide clinicians toward the need for further testing, it is not a substitute for hemoglobin electrophoresis, which remains the gold standard for diagnosing thalassemia. The Mentzer Index can expedite the diagnostic process by identifying individuals who require further evaluation, making it a valuable tool in conjunction with more definitive tests.[17]

5. Mentzer Index vs. Genetic Testing

Genetic testing offers a definitive diagnosis of thalassemia by identifying mutations in the globin genes. While the Mentzer Index serves as a useful screening tool, genetic testing is essential for confirming the diagnosis, especially in ambiguous cases or for family planning purposes. The main advantage of the Mentzer Index lies in its accessibility and ease of use in clinical settings, allowing for rapid identification of at-risk individuals. However, for patients with a family history of thalassemia or those showing significant clinical signs, genetic testing becomes crucial for accurate diagnosis and management.[19]

6. Limitations of the Mentzer Index

While the Mentzer Index provides a quick and convenient means of screening for thalassemia traits, it is not without limitations. Its accuracy can be influenced by various factors, including ethnic background, hydration status, and the presence of concurrent medical conditions. Additionally, variations in hematological parameters across different populations may affect the cut-off values used for interpretation. It is essential for healthcare providers to recognize these limitations and use the Mentzer Index in conjunction with other diagnostic tools and clinical evaluations. A comprehensive approach will lead to better diagnostic accuracy and management of anemia during pregnancy.[19]

Challenges and Limitations

The use of the Mentzer Index as a screening tool for thalassemia traits presents several challenges and limitations that healthcare providers must consider when integrating it into clinical practice. These challenges can impact its effectiveness, accuracy, and overall utility in diagnosing and managing anemia, particularly in pregnant women.

1. Population Variability

One of the primary limitations of the Mentzer Index is its variability across different populations. Hematological parameters, such as mean corpuscular volume (MCV) and red blood cell (RBC) count, can differ based on genetic, environmental, and nutritional factors. For example, populations with a high prevalence of thalassemia traits may exhibit different cut-off values for the Mentzer Index compared to populations where thalassemia is less common. This variability necessitates population-specific studies to establish appropriate thresholds, which may not always be available.[19]

2. Influence of Other Hematological Conditions

The Mentzer Index is primarily designed to differentiate between thalassemia and iron deficiency anemia; however, its accuracy can be affected by the presence of other hematological disorders. Conditions such as anemia of chronic disease, sideroblastic anemia, and certain forms of hemolytic anemia can produce overlapping laboratory findings, complicating the interpretation of the Mentzer Index. In these cases, reliance solely on the index without further diagnostic evaluation can lead to misdiagnosis.[17]

3. Limited Diagnostic Power

While the Mentzer Index provides a useful preliminary assessment, it lacks the diagnostic power of definitive tests such as hemoglobin electrophoresis or genetic testing. A low Mentzer Index value suggests a higher likelihood of thalassemia, but it does not confirm the diagnosis. As a result, patients identified as at risk based on the Mentzer Index will require further testing to confirm the presence of thalassemia traits, which can lead to delays in diagnosis and management.[18]

4. Need for Clinical Context

The interpretation of the Mentzer Index must be done in the context of the patient's clinical presentation and history. Factors such as age, sex, nutritional status, and the presence of comorbidities can all influence red blood cell parameters and the resulting index calculation. Clinicians must consider these factors to avoid misinterpretation of the results. Without this contextual understanding, the Mentzer Index may lead to inappropriate management decisions.[15]

5. Dependence on Accurate Laboratory Measurements

The reliability of the Mentzer Index is contingent upon the accuracy of the underlying laboratory measurements of MCV and RBC count. Any discrepancies or errors in these measurements can significantly impact the calculation of the index, leading to false interpretations. Variability in laboratory techniques, equipment calibration, and personnel training can all contribute to inaccuracies, highlighting

the importance of standardization in laboratory practices.[16]

6. Educational Gaps Among Healthcare Providers

For the Mentzer Index to be effectively utilized in clinical practice, healthcare providers must be adequately educated about its application, interpretation, and limitations. Inadequate training can lead to misunderstanding of the index, inappropriate application in clinical decision-making, and potential patient harm. Continuing education and training programs are essential to ensure that clinicians are equipped to use the Mentzer Index correctly.[17]

7. Access to Follow-Up Testing

While the Mentzer Index serves as a valuable screening tool, patients identified as needing further evaluation may face barriers to access definitive testing, such as hemoglobin electrophoresis or genetic testing. In resource-limited settings, the lack of access to specialized testing can hinder appropriate diagnosis and management of thalassemia traits, ultimately affecting maternal and fetal health outcomes.[18-19]

Conclusion

The Mentzer Index is a valuable screening tool for identifying thalassemia traits, particularly in pregnant women, where accurate diagnosis is crucial for maternal and fetal health. Its ability to differentiate between thalassemia and iron deficiency anemia through simple calculations of red blood cell indices provides clinicians with a practical approach to early detection. However, the index is not without its limitations, including population variability, influence from other hematological conditions, and the need for accurate laboratory measurements. While the Mentzer Index serves as an effective initial screening method, it should not be used in isolation. A comprehensive diagnostic approach, incorporating additional tests such as hemoglobin electrophoresis, genetic testing, and clinical evaluation, is essential for confirming the diagnosis and guiding appropriate management. Moreover, addressing educational gaps among healthcare providers regarding the application and interpretation of the Mentzer Index can enhance its effectiveness in clinical practice.

Conflict of Interest: The authors declare no potential conflict of interest with respect to the contents, authorship, and/or publication of this article.

Author Contributions: All authors have equal contribution in the preparation of manuscript and compilation.

Source of Support: Nil

Funding: The authors declared that this study has received no financial support.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data supporting in this paper are available in the cited references.

Ethics approval: Not applicable.

References

1. Rahman MM, Abe SK, Rahman MS, Kanda M, Narita S, Bilano V, Ota E, Gilmour S, Shibuya K. Maternal anemia and risk of adverse birth and health outcomes in low-and middle-income countries: systematic review and meta-analysis. The American journal of clinical nutrition. 2016; 103(2):495-504. https://doi.org/10.3945/ajcn.115.107896 PMid:26739036

2. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-8. https://doi.org/10.22270/ijmspr.v10i2.95

3. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research. 2017;5(4):206.

4. Petrakos G, Andriopoulos P, Tsironi M. Pregnancy in women with thalassemia: challenges and solutions. International journal of women's health. 2016:441-451. https://doi.org/10.2147/IJWH.S89308 PMid:27660493 PMCid:PMC5019437

5. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021 Apr;9(4):145-8.

6. Agreen FC, Obeagu EI. Anaemia among pregnant women: A review of African pregnant teenagers. Journal of Public Health and Nutrition. 2023;6(1):138.

7. Arora S, Rana D, Kolte S, Dawson L, Dhawan I. Validation of new indices for differentiation between iron deficiency anemia and beta thalessemia trait, a study in pregnant females. International Journal of Scientific Reports. 2018; 4(2):26. https://doi.org/10.18203/issn.2454-2156.IntJSciRep20180394

8. Tabassum S, Khakwani M, Fayyaz A, Taj N. Role of Mentzer index for differentiating iron deficiency anemia and beta thalassemia trait in pregnant women. Pakistan Journal of Medical Sciences. 2022;38(4Part-II):878. https://doi.org/10.12669/pjms.38.4.4635

9. Matos JF, Dusse LM, Stubbert RV, Ferreira MR, Coura-Vital W, Fernandes AP, de Faria JR, Borges KB, Carvalho MD. Comparison of discriminative indices for iron deficiency anemia and β thalassemia trait in a Brazilian population. Hematology. 2013 May 1;18(3):169-74. https://doi.org/10.1179/1607845412Y.0000000054 PMid:23321282

10. Iolascon A, Andolfo I, Russo R, Sanchez M, Busti F, Swinkels D, Aguilar Martinez P, Bou-Fakhredin R, Muckenthaler MU, Unal S, Porto G. Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia. Hemasphere. 2024; 8(7):e108. https://doi.org/10.1002/hem3.108 PMid:39011129 PMCid:PMC11247274

11. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of protein C, protein S and fibrinogen of pregnant women with malaria in Owerri metropolis. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Apr 19;2(2):1-9.

12. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58

13. Sahli CA, Bibi A, Ouali F, Fredj SH, Dakhlaoui B, Othmani R, Laouini N, Jouini L, Ouenniche F, Siala H, Touhami I. Red cell indices: differentiation between β-thalassemia trait and iron deficiency anemia and application to sickle-cell disease and sickle-cell thalassemia. Clinical Chemistry and Laboratory Medicine (CCLM). 2013; 51(11):2115-24. https://doi.org/10.1515/cclm-2013-0354 PMid:23800659

14. Hoffmann JJ, Nabbe KC, van den Broek NM. Effect of age and gender on reference intervals of red blood cell distribution width (RDW) and mean red cell volume (MCV). Clinical Chemistry and Laboratory Medicine (CCLM). 2015; 53(12):2015-9. https://doi.org/10.1515/cclm-2015-0155 PMid:26536583

15. Miftahussurur M, Husada D, Ningtyas WS. Association of shine and LAL index β-thalassemia trait screening results with anaemia and low birth weigh. international journal of nursing and midwifery science (IJNMS). 2023; 7(3):290-296. https://doi.org/10.29082/IJNMS/2023/Vol7/Iss3/543

16. Shahid H, Saleem M, Naseer N, Tabussam S, Aziz A, Ullah S. Evaluation of Srivastava index to distinguishing Beta-Thalassemia Trait from Iron Deficiency. Pakistan Journal of Medical & Health Sciences. 2022;16(05):1225-. https://doi.org/10.53350/pjmhs221651225

17. Vehapoglu A, Ozgurhan G, Demir AD, Uzuner S, Nursoy MA, Turkmen S, Kacan A. Hematological indices for differential diagnosis of Beta thalassemia trait and iron deficiency anemia. Anemia. 2014; 2014(1):576738. https://doi.org/10.1155/2014/576738 PMid:24818016 PMCid:PMC4003757

18. Urrechaga E. Discriminant value of % microcytic/% hypochromic ratio in the differential diagnosis of microcytic anemia. Clinical chemistry and laboratory medicine. 2008;46(12):1752-1758. https://doi.org/10.1515/CCLM.2008.355 PMid:19055451

19. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV- Exposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18 https://doi.org/10.22270/ajdhs.v4i2.82